Top Health-care stocks:
Health-care shares were mixed in pre-market trade Wednesday.
In health-care stocks news, Iovance Biotherapeutics ( IOVA ) said Wednesday it has dosed the first patient in its C-145-04 phase 2 trial of LN-145 for the treatment of recurrent, metastatic or persistent cervical carcinoma.
Shares in the company were unchanged at $4.70 in pre-market trade. The stock has traded between $4.60 and $9.57 over the past 52 weeks.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.